Medicinal cannabis in Germany - Business Report

5 Confidential 10.4 Dronabinol ....................................................................................................................164 10.5 Finished Cannabis medicinal products .............................................................................165 11. Forecast of Cannabis market development 2018-2023...............................................166 11.1 Framework conditions for market development and trend projections .............................166 11.2 Relevant factors influencing future market development .................................................169 11.3 Defined Daily Dose (DDD) in the Cannabis market ............................................................170 11.4 Trend projections of Cannabis prescriptions 2018-2023 ...................................................171 11.5 Trend projections of Cannabis sales 2018-2023 ...............................................................172 11.6 Trend projections for pharmacy purchases of Cannabis flowers 2018-2023 .......................173 11.7 Projection of market turnover ........................................................................................174 11.8 Trend projections of the Cannabidiol (CBD) sub-market ...................................................175 11.9 Prognosis of the sub-market Cannabis finished medicinal products ...................................177 11.9.1 Sativex® (Nabiximols) ......................................................................................................177 11.9.2 Canemes® (Nabilone) ......................................................................................................177 11.9.3 Marinol® (Dronabinol) .....................................................................................................177 11.9.4 Epidyolex® (Cannabidiol-CBD) .........................................................................................178 11.9.5 CannEpil® (CBD)...............................................................................................................178 11.10 Coverage of Cannabis patients in Germany 2019 to 2033 ...............................................179 Quintessence ..................................................................................................................181